Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10442186 | 0.82 | ALDH1A1 (0.54) | ALDH1A1KMT2AMEN1MAPTL3MBTL1 | |
| SCHEMBL15216575 | 0.82 | MAPT (0.58) | ALDH1A1KMT2AMEN1MAPTPOLB | |
| SCHEMBL10442450 | 0.79 | CYP17A1 (0.55) | ALDH1A1KMT2AMEN1MAPTCYP19A1 | |
| SCHEMBL257695 | 0.79 | L3MBTL1 (0.56) | ALDH1A1KMT2AMEN1MAPTPOLB | |
| SCHEMBL15216574 | 0.76 | SLC6A2 (0.62) | ALDH1A1KMT2AMEN1MAPTPOLB | |
| SCHEMBL4437809 | 0.76 | POLB (0.58) | ALDH1A1KMT2AMEN1MAPTPOLB | |
| SCHEMBL10038669 | 0.75 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1MAPTPOLB | |
| Pyrazine SCHEMBL27515795 | 0.74 | MAPT (0.65) | ALDH1A1MAPTPOLBNPC1RAB9A | |
| SCHEMBL545380 | 0.74 | — | — | |
| SCHEMBL15617656 | 0.74 | ALDH1A1 (0.56) | ALDH1A1KMT2AMEN1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579352-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-25 | — | — | US | disclosed |
| US-20080058334-A1 | Retinoic Acid Mimetic Anilides | MABIRE DOMINIQUE | 2008-03-06 | — | — | US | disclosed |
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | MABIRE DOMINIQUE | 2007-05-10 | — | — | US | disclosed |
| US-7179825-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-20 | — | — | US | disclosed |
| US-6936626-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-30 | — | — | US | disclosed |
| US-20050165018-A1 | Retinoic acid mimetic anilides | MABIRE DOMINIQUE (FR) | 2005-07-28 | — | — | US | disclosed |
| EP-1037880-B1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA NV (BE) | 2004-06-30 | — | — | EP | disclosed |
| US-20020115653-A1 | Retinoic acid mimetic anilides | MABIRE DOMINIQUE (FR) | 2002-08-22 | — | — | US | disclosed |
| US-6319939-B1 | P-(HETEROCYCLIC METHYL)-SUBSTUTED ANILIDES ARE POTENT INHIBITORS OF THE RETINOIC ACID METABOLISM | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-11-20 | — | — | US | disclosed |
| EP-1037880-A1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999029674-A1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115653-A1 | Retinoic acid mimetic anilides | RXRA, RXRB, RXRG | ALDH1A1 127/4885KMT2A 2932/4885MEN1 4443/4885 |
| US-20050165018-A1 | Retinoic acid mimetic anilides | RXRA, RXRB, RXRG | ALDH1A1 188/4885KMT2A 3958/4885MEN1 3649/4885 |
| US-20080058334-A1 | Retinoic Acid Mimetic Anilides | RXRA, RXRB, RXRG | ALDH1A1 187/4885KMT2A 3811/4885MEN1 3705/4885 |
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | RXRA, RXRB, RXRG | ALDH1A1 188/4885KMT2A 3958/4885MEN1 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.